← Back to Clinical Trials
Recruiting NCT06745830

NCT06745830 Lymph Node Pathologic Grading Strategy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06745830
Status Recruiting
Phase
Sponsor Fudan University
Condition Lung Adenocarcinoma
Study Type OBSERVATIONAL
Enrollment 2,998 participants
Start Date 2024-04-10
Primary Completion 2024-12-30

Trial Parameters

Condition Lung Adenocarcinoma
Sponsor Fudan University
Study Type OBSERVATIONAL
Phase N/A
Enrollment 2,998
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2024-04-10
Completion 2024-12-30
Interventions
No intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The percentage of high-grade patterns in metastatic LNs (mLNs) that can predict poor outcomes has yet to be determined. Additionally, the potential implications of other histologic patterns in metastatic lymph nodes on patient outcomes warrant further investigation. We conducted a retrospective cohort study to investigate the prognostic value of pathologic pattern in metastatic lymph nodes.

Eligibility Criteria

Inclusion Criteria: From January 2011 to September 2021, we consecutively collected patients with invasive LUAD who underwent surgical resection at the Department of Thoracic Surgery, Fudan University Shanghai Cancer Center. Exclusion Criteria: 1. adenocarcinoma in situ, minimally invasive adenocarcinoma, invasive mucinous adenocarcinoma, and other variants of adenocarcinoma; 2. incomplete common driver mutation data; 3. unavailable pathologic slides.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology